SQI Diagnostics | GenomeWeb

SQI Diagnostics

NEW YORK (GenomeWeb) – Toronto-based SQI Diagnostics continues to see its CustomPlex diagnostic tools and services business generate revenue as interest in its technology from pharmaceutical industry partners increases.

Trilochan Sahoo is CombiMatrix's new director of cytogenetics. Sahoo joins the Irvine, Calif.-based molecular testing services firm from Quest Diagnostics Nichols Institute, where he was senior director of cytogenetics. He also served as laboratory director at Signature Genomics.

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI Diagnostics today announced it raised gross proceeds of C$4.2 million (US$3.8 million) in a public offering.

NEW YORK (GenomeWeb News) – Health Canada has issued a license to SQI Diagnostics allowing the company to market its multiplexed Ig_plex Celiac DGP Panel, the Toronto-based firm said today.

NEW YORK (GenomeWeb News) – Toronto-based life sciences and diagnostics company SQI Diagnostics today announced a method development deal with Isis Pharmaceuticals.

Andrew Morris has joined SQI Diagnostics' board of directors.

NEW YORK (GenomeWeb News) – Microarray-based diagnostics firm SQI Diagnostics today reported zero revenues for its fiscal second quarter.

NEW YORK (GenomeWeb News) – SQI today said it has raised almost C$3.85 million (US$3.81 million) in a non-brokered private placement of its stock.

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced a non-brokered private placement intended to raise C$3.76 million (US$3.72 million) in gross proceeds.

SQI Diagnosticsand Algorithme Pharma have developed a microarray-based assay targeted at the immunogenicity testing of heparin and heparin-based low molecular weight biosimilar compounds.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.